Prognostic value of 18 F-fluorodeoxyglucose positron emission tomography/computed tomography at diagnosis in untreated multiple myeloma patients: a systematic review and meta-analysis

Multiple myeloma is a clonal B-lymphocyte tumor of terminally differentiated plasma cells. 18 F-FDG PET/CT can provide valuable data for the diagnosis, restaging, and evaluate prognosis of multiple myeloma (MM). This meta-analysis aimed to evaluate the prognostic value of pre-treatment 18 F-FDG PET/CT at diagnosis in MM patients. Related researches came from Embase, PubMed, and Cochrane Library databases through a systematic search, and the last one was updated on April 26, 2021. Cochran Q test and I-squared statistics were used to test for heterogeneity among the studies analyzed. The fixed model and random model were used to combine results when appropriate. Stata 12.0 was used to perform statistical analysis, and p < 0.05 was considered statistically significant. A total of 16 articles with 2589 patients were included in this study. Our results indicated PET/CT has an excellent prognostic role in MM, that higher SUV max , more FL and EMD were associated with poor OS and PFS. SUVmax: OS (HR 1.89, 95% CI 1.47–2.44), PFS (HR 1.34, 95% CI 1.18–1.51); Fl: OS (HR 2.65, 95% CI 1.83–3.79), PFS (HR 1.61, 95% CI 1.40–1.86); EMD: OS (HR 2.11, 95% CI 1.41–3.16), PFS (HR 2.18, 95% CI 1.69–2.81). Furthermore, similar results were observed in most subgroup analyzes. Conclusion Pre-treatment 18 F-FDG PET/CT examination has prognostic value for myeloma patients and has guiding significance for clinical treatment.